Real World Data
The place of real-world evidence in the market access strategy

The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in Real-world challenges and real-world data, understanding the payer’s perspective, in Payers use real-world data cautiously, and seeing the views of both advocates and opponents of […]

Real-world data
Is real-world evidence the holy grail: Finding the balance

We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer’s perspective, in Payers use real-world data cautiously. In our third instalment, we’re looking at how to find the right balance in using RWE. With the rapidly growing availability of […]

Real World Data Market Access
Payers use real-world data cautiously

Following our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in our blog Real-world challenges and real-world data, the second instalment of our four-blog series looks at why payers use real-world data cautiously. While companies and regulators are becoming increasingly enthusiastic about RWD and RWE, payers remain cautious. They’re using concerns […]

real-world data
Real-world challenges and real-world data

This is the first of a set of four blogs on real-world data (RWD) and real-world-evidence (RWE), and their role in market access. RWD and RWE are high on the list of priorities for the top 20 pharmaceutical companies. According to Deloitte, 90% of them are investing in RWE capabilities across the entire product lifecycle. […]

Patient-reported outcome measures
Patient-reported outcome measures: Choose with care

Patient-reported outcome measures are increasingly important in the assessment of treatment regimes, both for regulatory approval and for market access. However, selecting the most appropriate measure and interpreting the data can be challenging.

orphan drug
Patient advocacy as a strategy for orphan drug access

Governments have integrated incentives to accelerate and promote the approval of orphan drugs and the interest among pharmaceutical companies to develop these products is rising. However, expedited regulatory approval is by no means an assurance that orphan drugs will succeed in the marketplace.

Pharma Market Access
Big data insights for market access: To trust or not to trust?

Big data reportedly houses so much clinical and commercial insight that, once unlocked, it can increase our understanding of customers and markets, while also informing the design, development, and marketing of biopharmaceutical products and services. It can also drive positive health and economic outcomes. With tremendous volumes of data, companies have more resources (in the […]

PRO data
Curbing non-adherence with PRO data

On average, it is estimated that over 50% of patients eventually abandon their treatment. Patient-reported outcomes (PROs) could facilitate efforts to reduce these figures. Defined as any data coming directly from patients about how they feel or function in relation to a health condition or its treatment – with no clinician interpretation to remove the […]

Real World Evidence
Designing studies to show real-world value

There is a gap between scientific knowledge and daily medical practice. Although there may be major science breakthroughs, this does not directly translate into new treatments available to patients. New products from research and development can only be translated into medical practice if they are reimbursed by payers. In pharmaceuticals and biotech, there are two […]

Real-world patient data
Generating insights with real-world patient data

Generation of real-world data is on the increase, from smartphones and social media to medical records and clinical trials. This wealth of data has a huge amount of potential, but in order to make the most of it, life science companies need to focus on generating the right kind of insights from the megabytes of […]